Tag: Regeneron
COVID antibody drugs from Lilly and Regeneron won’t do much to...
When Eli Lilly won emergency use authorization for its COVID-19 antibody drug, bamlanivimab, earlier this week, beating Regeneron to the finish line in a...
Watch out, Merck: FDA grants Regeneron, Sanofi’s Libtayo priority review for...
One month after Regeneron and Sanofi posted impressive data from a phase 3 trial of their PD-1 inhibitor Libtayo in first-line non-small cell lung...
Roche, Regeneron join forces to more than triple manufacturing of COVID-19...
Despite hundreds of potential therapies for COVID-19 looking to make their case, very few have crossed the finish line. One promising candidate, Regeneron's two-antibody...
Pharma’s TV ad spending level sets in June, with AbbVie, Sanofi...
While pharma TV spending dipped in June, it was actually a back-to-normal summer month. The top 10 TV buyers' total spending was $141 million,...
MedCity Pivot Podcast: An interview with Bari Kowal, vice president of...
Regeneron Pharmaceuticals, one of the companies taking on Covid-19 has been making news recently — both very good and not so much. So it...
Regeneron CEO: Manufacturing not up to snuff for COVID-19 vaccines, therapies
Regeneron has been at the forefront of the COVID-19 fight for months with partnered med Kevzara in clinical trials and an antibody cocktail in development....
